Polypharmacy in psychiatry: A review

Mens Sana Monographs

Volumn 11, Issue 1, 2013, Pages 82-99

  Kukreja, Sanjay ^a   Kalra, Gurvinder ^b   Shah, Nilesh ^a   Shrivastava, Amresh ^c  

^a Sion General Hospital   (India)

^b MGM Institute of Health Sciences   (India)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Drug combinations; multiple medications; polypharmacy; psychopharmacology

Indexed keywords

EID: 84876865845     PISSN: 09731229     EISSN: 19984014     Source Type: Journal    
DOI: 10.4103/0973-1229.104497     Document Type: Review

References (57)

1. Anthierens S, Tansens A, Petrovic M, Christiaens T. Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract 2010;11:65.
2. Baandrup L, Allerup P, Nordentoft M, Lublin H, Glenthoj BY. Exploring regional variation in antipsychotic coprescribing practice: A Danish questionnaire survey. J Clin Psychiatry 2010;71:1457-64.
3. Campos RN, Costa LF, Bio DS, de Souza MG, Garcia CR, Demétrio FN, et al. LICAVAL: Combination therapy in acute and maintenance treatment of bipolar disorder. Trials. 2010;11:72.
4. Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006;57:1094-101.
5. Chong SA, Ravichandran N, Poon LY, Soo KL, Verma S. Reducing polypharmacy through the introduction of a treatment algorithm: Use of a treatment algorithm on the impact on polypharmacy. Ann Acad Med Singapore 2006;35:457-60.
6. Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry 2010;49:1001-10.
7. David T. Antipsychotic prescribing-time to review practice. Psychiatric Bulletin 2002;26:401-2.
8. De las Cuevas C, Sanz EJ. Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry 2004;4:18.
9. Englisch S, Zink M. Treatment-resistant Schizophrenia: Evidence-based Strategies. Mens Sana Monogr 2012;10:20-32.
10. Evers K. Personalized medicine in psychiatry: Ethical challenges and opportunities. Dialogues Clin Neurosci 2009;11:427-34.
11. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323-30.
12. Freudenreich O, Kontos N, Querques J. Psychiatric polypharmacy: A clinical approach based on etiology and differential diagnosis. Harv Rev Psychiatry 2012;20:79-85.
13. Ghaemi SN. Polypharmacy in psychiatry. New York: Marcel Dekker; 2002.
14. Goh YL, Seng KH, Chuan AS, Chua HC. Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia. Perm J 2011 Spring; 15:52-6.
15. Isaacs D, Fitzgerald D. Seven alternatives to evidence based medicine. BMJ 19998-25;319:1618.
16. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: Psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005;187:243-7.
17. Jörgensen T, Johansson S, Kennerfalk A, Wallander MA, Svärdsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001;35:1004-9.
18. Kennedy NB, Procyshyn RM. Rational antipsychotic polypharmacy. Can J Clin Pharmacol 2000 Autumn; 7:155-9.
19. Ketter TA. Strategies for monitoring outcomes in patients with bipolar disorder. Prim Care Companion J Clin Psychiatry 2010;12:10-6.
20. Kingsbury SJ, Yi D, Simpson GM. Psychopharmacology: rational and irrational polypharmacy. Psychiatr Serv 2001;52:1033-6.
21. Lapane KL, Waring ME, Schneider KL, Dubé C, Quilliam BJ. A mixed method study of the merits of e-prescribing drug alerts in primary care. J Gen Intern Med 2008;23:442-6.
22. Lee RD. Polypharmacy: A case report and new protocol for management. J Am Board Fam Pract 1998;11:140-4.
23. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivelä SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002;55:809-17.
24. López-Torres Hidalgo J, Cerdá Díaz R, Fernández Olano C, Requena Gallego M, Fernández Casalderrey C, Otero Puime A. Factors associated with chronic drug consumption in the elderly. Med Clin (Barc) 1997;108:572-6.
25. Loyola Filho AI, Uchoa E, Firmo JO, Lima-Costa MF. Influence of income on the association between cognitive impairment and polypharmacy: Bambuí Project. Rev Saude Publica 2008;42:89-99.
26. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003;64:984-9.
27. Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: A cross-sectional study. BMC Psychiatry 2011;11:118.
28. Mojtabai R, Olfson M. National trends in psychotherapy by office-based psychiatrists. Arch Gen Psychiatry 2008;65:962-70.
29. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010;67:26-36.
30. Murray MD, Kroenke K. Polypharmacy and medication adherence: small steps on a long road. J Gen Intern Med 2001;16:137-9.
31. Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Di Nardo F, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. Schizophr Res 2011;127:93-9.
32. National Association of State Mental Health Program Directors: Technical Report on Psychiatric Polypharmacy. Medical Directors Council and State Medicaid Directors. Alexandria, Virginia; 2001.
33. Niculescu AB, Hulvershorn L. Toward Early, Personalized, Rational Polypharmacy In Psychiatry: A Tri-Dimensional Approach. Psychopharm Review 2010;45:9-16.
34. Owen RR, Fischer EP, Kirchner JE, Thrush CR, Williams DK, Cuffel BJ, et al. Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. Am J Med Qual 2003;18:140-6.
35. Padmini DD, Amarjeeth R, Sushma M, Guido S. Prescription patterns of psychotropic drugs in hospitalized schizophrenic patients in a tertiary care hospital. Calicut Med J 2007;5:e3.
36. Presborn SH, Flockhart D. Guide to Psychiatric Drug Interactions. Primary Psychiatry 2006;13:35-64.
37. Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Psychiatr Pract 2007;13:97-105.
38. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001;46:334-9.
39. Ramadas S, Kuttichira P, Sumesh TP, Ummer SA. A study of an antipsychotic prescription pattern of patients with schizophrenia in a developing country. Indian J Psychol Med 2010;32:13-6.
40. Rittmannsberger H. The use of drug monotherapy in psychiatric inpatient treatment. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:547-51.
41. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: A systematic review of the role of the pharmacist. Drugs Aging 2003;20:817-32.
42. Royal College of Psychiatrists Consensus Statement on the Use of High Dose Antipsychotic Medication. Council Report CR26. London: Royal College of Psychiatrists; 1993.
43. Sawhney V, Chopra V, Kapoor B, Thappa JR, Tandon VR. Prescription trends in schizophrenia and manic depressive psychosis. J K Sci 2005;7;156-8.
44. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 2004;65:1597-600.
45. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73.
46. Shrivastava A, Johnston M, Terpstra K, Stitt L, Shah N. Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia. Indian J Psychiatry 2012;54:248-52.
47. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007;370:173-84.
48. Stahl SM. Antipsychotic polypharmacy: Evidence based or eminence based? Acta Psychiatr Scand 2002a; 106:321-2.
49. Stahl SM. Antipsychotic polypharmacy: Squandering precious resources? J Clin Psychiatry 2002b; 63:93-4.
50. Stahl SM. Stahl's essential pschopharmacology: Neuroscientific basis and practical applications. New York: Cambridge University Press; 2008.
51. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003;54:55-9.
52. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: A case note review. J Clin Psychiatry 2003;64:30-4.
53. Thompson A, Sullivan SA, Barley M, Strange SO, Moore L, Rogers P, et al. The DEBIT trial: An intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial. Psychol Med 2008;38:705-15.
54. Trivedi JK, Dhyani M, Yadav VS, Rai SB. Anti-psychotic drug prescription pattern for schizophrenia: Observation from a general hospital psychiatry unit. Indian J Psychiatry 2010;52:279.
55. Wang YC, Chen CY, Kuo TB, Lai CJ, Yang CC. Influence of antipsychotic agents on heart rate variability in male WKY rats: Implications for cardiovascular safety. Neuropsychobiology 2012;65:216-26.
56. Werder SF, Preskorn SH. Managing polypharmacy: Walking the fine line between help and harm. Curr Psychiatry 2003;2:24-36.
57. Williams DD, Garner J. The case against "the evidence": A different perspective on evidence-based medicine. Br J Psychiatry 2002;180:8-12.